World-first clinical trial launched for fridge-free vaccine that could revolutionise healthcare

The UK is paving the way for advancement with the launch of a first-of-its-kind clinical trial of a vaccine that doesn't require refrigeration. This could potentially revolutionise vaccine distribution.

This groundbreaking initiative tests the tetanus-diphtheria vaccine (SPVX02) developed by Stablepharma, which stays perfectly stable at ambient temperatures. The company is optimistic about leveraging this to help up to 60 other vaccines avoid the fridge.

Currently, the vaccine's human trial is underway at the National Institute for Health and Care Research (NIHR) Southampton clinical research facility situated in .

One of the major hurdles in immunization efforts, particularly in certain regions around the , is maintaining the "cold chain" – the vital cool conditions from production until administration of the vaccine.

READ MORE:

READ MORE:

According to the World Health Organisation (WHO), nearly half of the vaccines globally are discarded each year, with improper temperature control and cold-chain logistical issues largely to blame

.Stablepharma, a UK-based biotech firm, has demonstrated that it can transform existing, approved vaccines into non-refrigerated versions with the potential for long-term room temperature storage.

Health and Social Care Secretary Wes Streeting applauded the development: "For years, vaccines have been held back by the need to be stored in a fridge – causing endless amounts of wastage and making it difficult to deliver them to remote communities."

He heralded what may be a turning point brought by this cutting-edge research: "But thanks to this Government's vision and our investment through the National Institute for Health and Care Research, all that could be about to change."

“We are leading the charge by pushing through the world’s first trial for fridge-free vaccines.

"This could be a real game changer and lifesaver globally – as it unlocks new ways for poorer nations to deliver vaccines to their patients, where they're often needed the most."

The health secretary added: "Groundbreaking science is amongst the things that Britain does best, and this innovation reaffirms our position as a world leader in vaccine development and research, boosting growth and economic security – the cornerstone of our Plan for Change."

Professor Saul Faust from the University of Southampton and Dr Karen O'Hanlon, chief development officer at Stablepharma, are guiding the pivotal clinical trial.

Prof Faust said: "It is fantastic to see cutting-edge UK science reach the milestone of a first clinical trial and to be able to give the opportunity for people living on the south coast to take part.

"This research will be an important step toward exploring whether this innovation could eradicate vaccine wastage and move away from the need for the cold-chain."

Expectations are high that the study will wrap up by summer, with results awaiting release by year-end. With ambitious targets set by Stablepharma, the innovative vaccine could be deployed worldwide by 2027.